A significant number of Phase III clinical trials are over-collecting data because of overcomplicated protocol designs, leading to avoidable delays in drug development times, says a new report. 

Phesi used proprietary data from its Trial Accelerator Platform to analyse 2,401 industry-sponsored Phase III clinical trials that have reached their primary endpoint since January 2020, 1,574 of which had reported patient data so far. 

The top five diseases analysed by Phesi in the analysis were Covid-19, type 2 diabetes, atopic dermatitis, non-small cell lung cancer, and cystic fibrosis. 

From these, the company identified 146 protocols designed to capture 1,821 outcome measures, ranging between one and 102 measures per protocol, and including both primary and secondary outcomes. 

The analysis shows that the more outcome measures included in a trial protocol, the lower the percentage of those outcomes reported in results. On average, over a third (35%) of outcome measures were not reported. 

Trials with fewer than the median number of outcome measures in a protocol reported 94% of those measures in their results, whereas those that collected more than the median number of outcomes typically only reported 56% in their results. 

“Collecting a good amount of data is important for clinical trials, but it has to be the right data at the right time,” said Dr Gen Li, Founder and CEO of Phesi. “Many of the clinical trials we analysed had redundant outcome measures. For example, trials often use several different physical performance status measures on the same patients – which is a huge added burden for that patient even though each scale is measuring the same thing. This also puts undue pressure on investigator sites.” 

Clinical trial enrolment also affected

The analysis also showed a correlation between a lower number of outcome measures and better site enrolment, demonstrating that recruitment is improved when the trial protocol presents a smaller burden to the patients and investigator sites.  

Directly comparing type 2 diabetes trials from two different sponsors found that the sponsor using a median of 25 outcomes measures for their trials had lower site enrolment performance (10.2 patients per site vs. 11.2) and a lower enrolment rate (0.46 patients per site per month vs. 0.53) compared to the sponsor with a median of only 10 outcome measures. In the same indication of T2DM, one trial planned 39 outcome measures in the protocol, an outlier for a median of 10 outcome measures. While originally planned to complete in 19 months, it overran by seven months, completing in 26 months instead. 

View the full report here: https://info.phesi.com/trial-complexity-report 

Diana Spencer, Senior Digital Content Editor, DDW